Universal HCV testing, community-based prevention, and peer navigators can help curb a decade-long surge in new US hepatitis ...

The FDA on Friday approved a subcutaneous (SC) induction regimen for risankizumab-rzaa (Skyrizi; AbbVie) in adults with moderately to severely active Crohn disease, giving patients the option to begin ...

Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.

OneOncology's Larry Bilbrey outlines network-level contracting, data security, physician review of AI output, and clear ...

Recognizing Typical Lesions, Locations, and Chronicity" takes up the question of how clinicians can recognize HS reliably. Dr ...

Two new approvals reshape the complicated UTI landscape within a single year: an intravenous option revived after ...

CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in ...

Senu Apewokin, MD, explains why C diff in ICU and chemotherapy patients may reflect colonization, not hospital transmission.

Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.

UW Medicine’s Bessie A. Young, MD, MPH, explains how high-risk APOL1 variants, ancestry, and environmental factors shape kidney disease risk.

Providence’s Katherine R. Tuttle, MD, FASN, explains why semaglutide is preferred in T2D and CKD and how guidelines sequence ...

Relapse outcomes were largely null in major RCTs, including SOLAR and VIDAMS, despite numerically lower ARR in some analyses ...